Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab with carboplatin and etoposide in untreated extensive-stage small cell lung cancer
2019-003301-97Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tiragolumab + atezolizumab + carboplatin + etoposide with Placebo + atezolizumab + carboplatin + etoposide (2 arms). Primary endpoint: Progression-free survival in the primary analysis set. Started Apr 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2019-003301-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003301-97.